|
WO2010080835A1
(en)
|
2009-01-06 |
2010-07-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention oral infections by e. coli
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
EA021113B1
(ru)
|
2009-09-03 |
2015-04-30 |
Бристол-Майерс Сквибб Кампани |
Хиназолины в качестве ингибиторов калиевых каналов
|
|
US9511125B2
(en)
|
2009-10-21 |
2016-12-06 |
Curemark Llc |
Methods and compositions for the treatment of influenza
|
|
WO2012097013A1
(en)
|
2011-01-10 |
2012-07-19 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
GB201114212D0
(en)
|
2011-08-18 |
2011-10-05 |
Ucb Pharma Sa |
Therapeutic agents
|
|
WO2013068592A1
(en)
*
|
2011-11-10 |
2013-05-16 |
Fondation Jerome Lejeune |
Inhibitors of cystathionine beta synthase to reduce the neurotoxic overproduction of endogenous hydrogen sulfide
|
|
AR090037A1
(es)
|
2011-11-15 |
2014-10-15 |
Xention Ltd |
Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
|
|
JP6126131B2
(ja)
*
|
2012-01-10 |
2017-05-10 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
EP2806875B1
(en)
*
|
2012-01-25 |
2017-07-19 |
Proteostasis Therapeutics, Inc. |
Proteasome activity modulating compounds
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
EP2671575A1
(en)
*
|
2012-06-04 |
2013-12-11 |
Universität Regensburg |
Ras inhibitors
|
|
LT2858987T
(lt)
|
2012-06-11 |
2018-07-10 |
Bristol-Myers Squibb Company |
Fosforamido rūgšties provaistai iš 5-[5-fenil-4-(piridin-2-ilmetilamino)chinazolin-2-il]piridin-3-sulfonamido
|
|
WO2014011906A2
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014011902A1
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2892534B8
(en)
*
|
2012-09-06 |
2021-09-15 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
KR102215272B1
(ko)
*
|
2012-09-28 |
2021-02-15 |
이그니타, 인코포레이티드 |
비정형 단백질 키나제 c의 아자퀴나졸린 억제제
|
|
GB201217704D0
(en)
*
|
2012-10-03 |
2012-11-14 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US20140136295A1
(en)
|
2012-11-13 |
2014-05-15 |
Apptio, Inc. |
Dynamic recommendations taken over time for reservations of information technology resources
|
|
CA2890911A1
(en)
|
2013-01-10 |
2014-07-17 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014127191A1
(en)
|
2013-02-15 |
2014-08-21 |
The Regents Of The University Of Michigan |
Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins
|
|
WO2014164543A1
(en)
*
|
2013-03-13 |
2014-10-09 |
The Regents Of The University Of Michigan |
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
CN104119343A
(zh)
*
|
2013-04-25 |
2014-10-29 |
苏州科捷生物医药有限公司 |
2-三氟甲基噻二唑类化合物及其用途
|
|
CN106232122A
(zh)
|
2013-09-27 |
2016-12-14 |
林伯士艾瑞斯公司 |
Irak抑制剂和其用途
|
|
TWI648281B
(zh)
*
|
2013-10-17 |
2019-01-21 |
日商安斯泰來製藥股份有限公司 |
含硫二環式化合物
|
|
JP2017001954A
(ja)
*
|
2013-11-08 |
2017-01-05 |
石原産業株式会社 |
含窒素飽和複素環化合物
|
|
CN104892589A
(zh)
|
2014-03-07 |
2015-09-09 |
中国科学院上海药物研究所 |
一类杂环化合物、其制备方法和用途
|
|
EP3116867A4
(en)
*
|
2014-03-11 |
2017-10-18 |
Godavari Biorefineries Ltd. |
Cancer stem cell targeting compounds
|
|
USRE49687E1
(en)
|
2014-09-09 |
2023-10-10 |
The Regents Of The University Of Michigan |
Thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
WO2016081732A1
(en)
|
2014-11-19 |
2016-05-26 |
Memorial Sloan-Kettering Cancer Center |
Thienopyrimidines and uses thereof
|
|
CN104592248A
(zh)
*
|
2014-12-31 |
2015-05-06 |
芜湖杨燕制药有限公司 |
一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法
|
|
TWI703150B
(zh)
*
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
|
|
HK1246593A1
(zh)
|
2015-06-04 |
2018-09-14 |
Kura Oncology, Inc. |
用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
US10869868B2
(en)
|
2016-01-26 |
2020-12-22 |
Memorial Sloan Kettering Cancer Center |
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
|
|
PH12018501955B1
(en)
|
2016-03-16 |
2024-01-24 |
Kura Oncology Inc |
Bridged bicyclic inhibitors of menin-mll and methods of use
|
|
PL3429591T3
(pl)
*
|
2016-03-16 |
2023-07-17 |
Kura Oncology, Inc. |
Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
|
|
JP6991585B2
(ja)
|
2016-05-02 |
2022-01-12 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
メニン阻害剤としてのピペリジン
|
|
WO2017207387A1
(en)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
|
|
WO2018024602A1
(en)
|
2016-08-04 |
2018-02-08 |
Bayer Aktiengesellschaft |
2,7-diazaspiro[4.4]nonanes
|
|
CA3033239A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-mll interaction
|
|
EP3512857B1
(en)
*
|
2016-09-14 |
2021-02-24 |
Janssen Pharmaceutica NV |
Spiro bicyclic inhibitors of menin-mll interaction
|
|
CA3033020A1
(en)
*
|
2016-09-14 |
2018-03-22 |
Janssen Pharmaceutica Nv |
Fused bicyclic inhibitors of menin-mll interaction
|
|
US12084462B2
(en)
|
2016-09-14 |
2024-09-10 |
Janssen Pharmaceutica Nv |
Spiro bicyclic inhibitors of menin-MLL interaction
|
|
KR20190084063A
(ko)
|
2016-10-28 |
2019-07-15 |
이칸 스쿨 오브 메디슨 엣 마운트 시나이 |
Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
|
|
WO2018106870A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
CN110248946B
(zh)
*
|
2016-12-15 |
2023-05-23 |
詹森药业有限公司 |
Menin-MLL相互作用的氮杂环庚烷抑制剂
|
|
WO2018109088A1
(en)
|
2016-12-15 |
2018-06-21 |
Janssen Pharmaceutica Nv |
Azepane inhibitors of menin-mll interaction
|
|
EA038388B1
(ru)
*
|
2017-01-16 |
2021-08-19 |
Кура Онколоджи, Инк. |
Замещенные ингибиторы менина-mll и способы применения
|
|
WO2018175746A1
(en)
|
2017-03-24 |
2018-09-27 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and ewing's sarcoma
|
|
MX2019011412A
(es)
|
2017-03-31 |
2020-02-07 |
Univ Michigan Regents |
Piperidinas como inhibidores de menina covalentes.
|
|
WO2018226976A1
(en)
|
2017-06-08 |
2018-12-13 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
EP3684361A4
(en)
|
2017-09-20 |
2021-09-08 |
Kura Oncology, Inc. |
SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
|
|
JP7307729B2
(ja)
|
2017-12-20 |
2023-07-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
|
|
US11396517B1
(en)
|
2017-12-20 |
2022-07-26 |
Janssen Pharmaceutica Nv |
Exo-aza spiro inhibitors of menin-MLL interaction
|
|
JP2021515013A
(ja)
|
2018-03-06 |
2021-06-17 |
アイカーン スクール オブ メディスン アット マウント シナイ |
セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
|
|
US11325921B2
(en)
|
2018-03-30 |
2022-05-10 |
Sumitomo Dainippon Pharma Co., Ltd. |
Optically active crosslinked cyclic secondary amine derivative
|
|
EP3810145A4
(en)
|
2018-06-21 |
2022-06-01 |
Icahn School of Medicine at Mount Sinai |
Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
|
|
CA3112340A1
(en)
|
2018-10-03 |
2020-04-09 |
The Regents Of The University Of Michigan |
Small molecule menin inhibitors
|
|
JP7503851B2
(ja)
|
2019-05-06 |
2024-06-21 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
|
|
WO2021063346A1
(zh)
*
|
2019-09-30 |
2021-04-08 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
|
WO2021067215A1
(en)
|
2019-09-30 |
2021-04-08 |
Agios Pharmaceuticals, Inc. |
Piperidine compounds as menin inhibitors
|
|
TW202525813A
(zh)
|
2019-12-19 |
2025-07-01 |
比利時商健生藥品公司 |
經取代之直鏈螺環接衍生物
|
|
CN111297863B
(zh)
*
|
2020-03-30 |
2021-06-25 |
四川大学华西医院 |
menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
|
|
TW202204333A
(zh)
|
2020-04-08 |
2022-02-01 |
美商阿吉歐斯製藥公司 |
Menin抑制劑及治療癌症之使用方法
|
|
WO2021207310A1
(en)
|
2020-04-08 |
2021-10-14 |
Agios Pharmaceuticals, Inc. |
Menin inhibitors and methods of use for treating cancer
|
|
US12103924B2
(en)
|
2020-06-01 |
2024-10-01 |
Icahn School Of Medicine At Mount Sinai |
Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
WO2022086937A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Icahn School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of enl
|
|
CA3215379A1
(en)
|
2021-05-08 |
2022-11-17 |
Olivier Alexis Georges Querolle |
Substituted spiro derivatives
|
|
US20240417405A1
(en)
|
2021-05-08 |
2024-12-19 |
Janssen Pharmaceutica Nv |
Substituted Spiro Derivatives
|
|
IL308862A
(en)
|
2021-06-01 |
2024-01-01 |
Janssen Pharmaceutica Nv |
Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
|
|
JP2024521902A
(ja)
|
2021-06-03 |
2024-06-04 |
ヤンセン ファーマシューティカ エヌ．ベー． |
スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
|
|
WO2022262796A1
(en)
|
2021-06-17 |
2022-12-22 |
Janssen Pharmaceutica Nv |
(r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
|
|
WO2023056589A1
(en)
|
2021-10-08 |
2023-04-13 |
Servier Pharmaceuticals Llc |
Menin inhibitors and methods of use for treating cancer
|
|
CN120529900A
(zh)
|
2022-11-24 |
2025-08-22 |
奥莱松基因组股份有限公司 |
用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
|